Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JACC Heart Fail
Autors principals: Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene
Format: Artigo
Idioma:Inglês
Publicat: by the American College of Cardiology Foundation. Published by Elsevier. 2020
Matèries:
Focus Issue: Angiotensin-Neprilysin Inhibition: Novel Insights
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://ncbi.nlm.nih.gov/pubmed/32641226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2020.05.005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars